Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DK8X
|
|||
| Former ID |
DNCL003507
|
|||
| Drug Name |
BMS-911543
|
|||
| Synonyms |
BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [1], [2] | |
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C23H28N8O
|
|||
| Canonical SMILES |
CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6
|
|||
| InChI |
1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)
|
|||
| InChIKey |
JCINBYQJBYJGDM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1271022-90-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7954). | |||
| REF 2 | Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.